Claessen BE, et al. - In the multicenter randomized DARE trial, researchers compared treatment outcomes between diabetic patients with BMS or DES in-stent restenosis (ISR) who were randomized in a 1:1 fashion to treatment with a paclitaxel-eluting balloon (PEB) or an everolimus-eluting stent (EES). After 6 months, they performed angiography on participants. There were 278 patients enrolled, of whom 88 (32%) had diabetes mellitus (DM), of whom 46 were randomized to EES and 42 to PEB treatment. DES-ISR was present in 48 (55%) of patients with DM. In the PEB group and in the DES group, angiographic follow-up was available for 30 patients (72%) and 36 patients (78%), respectively. Findings revealed similar 6-months in-segment minimal lumen diameter and comparable rates of major adverse events with the use of a PEB in patients with ISR and DM. In addition, the use of a PEB resulted in significantly lower in-segment late loss at 6 months. Based on these findings, PEB affords a promising treatment option removing the need for additional stent implantation.